<code id='CE1CC14525'></code><style id='CE1CC14525'></style>
    • <acronym id='CE1CC14525'></acronym>
      <center id='CE1CC14525'><center id='CE1CC14525'><tfoot id='CE1CC14525'></tfoot></center><abbr id='CE1CC14525'><dir id='CE1CC14525'><tfoot id='CE1CC14525'></tfoot><noframes id='CE1CC14525'>

    • <optgroup id='CE1CC14525'><strike id='CE1CC14525'><sup id='CE1CC14525'></sup></strike><code id='CE1CC14525'></code></optgroup>
        1. <b id='CE1CC14525'><label id='CE1CC14525'><select id='CE1CC14525'><dt id='CE1CC14525'><span id='CE1CC14525'></span></dt></select></label></b><u id='CE1CC14525'></u>
          <i id='CE1CC14525'><strike id='CE1CC14525'><tt id='CE1CC14525'><pre id='CE1CC14525'></pre></tt></strike></i>

          Home / entertainment / focus

          focus


          focus

          author:knowledge    Page View:21794
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In